Table 4

ACUITY: Ischemic Composite End Point (Death, MI, Unplanned Revascularization for Ischemia), Stent Thrombosis, and Mortality

UFH/Enoxaparin + GP IIb/IIIa (n = 4,516)Bivalirudin + GP IIb/IIIa (n = 4,502)Bivalirudin Alone (n = 4,521)p1Valuep2Value
Ischemic composite end point
 30 days7.4%7.8%7.9%0.360.38
 1 yr16.3%16.5%16.4%0.340.31
Stent thrombosis
 30 days1.3%1.6%1.3%0.390.97
 1 yr1.0%0.8%0.5%0.780.52
Morality
 30 days1.4%1.6%1.6%0.530.39
 1 yr4.4%4.2%3.8%0.930.66

p1= Bivalirudin + GPI versus UFH/Enoxaparin + GPI; p2= Bivalirudin alone versus UFH/Enoxaparin + GPI.

GP = glycoprotein; GPI = glycoprotein inhibitor; UFH = unfractioned heparin.